Status message

Active context: kki_bg_colors_yellow

The IBMD-OI Study: A Study to Assess the Effectiveness of Teriparatide (FORTEO)

Principal Investigator:

Sponsored by Eli Lilly and Company, the primary aim of this study is to assess whether an increase in BMD will result from the use of rhPTH. Furthermore, PTH has been shown to have effects on bone structure that may be beneficial (increased cortical thickness, trabecular number, bone size) and thus we will determine if PTH improves bone geometry in OI. A secondary aim is to determine if PTH therapy will decrease fragility fractures in individuals affected with OI. We contend that the results of this small study will provide data that will set the stage for larger, more definite studies. Specifically, preliminary results from these studies, if promising, will be used to support applications to the NIH for larger studies powered for a primary fracture outcome.

Bradley L. Schlaggar, M.D., Ph.D., Named President and CEO of Kennedy Krieger Institute

We’re thrilled to welcome Bradley L. Schlaggar, M.D., Ph.D., to the Kennedy Krieger family as our next President and CEO.
Learn more.


Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.